RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

RenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue Estimates

RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement

RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

RenovoRx Announces $10 Million at Market Private Placement

RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting

RenovoRx Establishes RenovoCath® Medical Advisory Board

RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026

RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

RenovoRx, Inc. (RNXT) Reports Q3 Loss, Lags Revenue Estimates

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights